For how we live.
Physically acting out dreams is one of the strongest known early signs of Parkinson's and related diseases. In a 1,280-patient cohort, most converted within 12 years — but it is a risk marker, not a verdict.
In HIMALAYA, 305 people with ALS took the RIPK1 inhibitor SAR443820 or placebo; function fell almost identically in both, and the sponsor is halting the drug in ALS.
In half a million Chinese adults, higher exhaled carbon monoxide tracked with lower Parkinson's risk even among people who never smoked. It is an association, not a therapy.
A once-daily experimental pill beat placebo in a phase 3 trial and is under regulatory review — yet no study has tested its claimed edge over older dopamine agonists head-to-head.
The anti-alpha-synuclein antibody did not significantly delay motor progression in the phase 2b PADOVA study, though a non-significant trend and secondary signals keep a phase 3 trial alive.
A 220,000-person cohort found opposite associations for two neurodegenerative diseases depending on the type and distance of greenery. Two other February papers ask who can actually use it.
Sequencing hundreds of single neurons from 15 donors with CTE and 4 with repetitive head impacts but no CTE, researchers found the genomic damage tracked the disease, not the exposure.